SI1050531T1 - Pyridine and piperidine derivatives for treating neurodegenerative diseases - Google Patents

Pyridine and piperidine derivatives for treating neurodegenerative diseases

Info

Publication number
SI1050531T1
SI1050531T1 SI200030565T SI200030565T SI1050531T1 SI 1050531 T1 SI1050531 T1 SI 1050531T1 SI 200030565 T SI200030565 T SI 200030565T SI 200030565 T SI200030565 T SI 200030565T SI 1050531 T1 SI1050531 T1 SI 1050531T1
Authority
SI
Slovenia
Prior art keywords
pyridine
group
alkoxy
piperidine
piperidine derivatives
Prior art date
Application number
SI200030565T
Other languages
English (en)
Slovenian (sl)
Inventor
Otto Meth-Cohn
Chu-Yi Yu
Pierre Lestage
Marie-Cecile Lebrun
Daniel-Henri Caignard
Pierre Renard
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of SI1050531T1 publication Critical patent/SI1050531T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SI200030565T 1999-05-05 2000-05-02 Pyridine and piperidine derivatives for treating neurodegenerative diseases SI1050531T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905690A FR2793245B1 (fr) 1999-05-05 1999-05-05 Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP00401198A EP1050531B1 (fr) 1999-05-05 2000-05-02 Composés pyridiniques ou pipéridiniques substitués pour le traitement des maladies neurodégénératives

Publications (1)

Publication Number Publication Date
SI1050531T1 true SI1050531T1 (en) 2005-04-30

Family

ID=9545222

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030565T SI1050531T1 (en) 1999-05-05 2000-05-02 Pyridine and piperidine derivatives for treating neurodegenerative diseases

Country Status (22)

Country Link
US (6) US6323220B1 (xx)
EP (1) EP1050531B1 (xx)
JP (2) JP3533361B2 (xx)
KR (1) KR100472519B1 (xx)
CN (1) CN100371326C (xx)
AT (1) ATE282595T1 (xx)
AU (1) AU764388B2 (xx)
BR (1) BR0002287A (xx)
CA (1) CA2308867C (xx)
DE (1) DE60015844T2 (xx)
DK (1) DK1050531T3 (xx)
EA (1) EA003053B1 (xx)
ES (1) ES2233302T3 (xx)
FR (1) FR2793245B1 (xx)
HU (1) HUP0001789A3 (xx)
MX (1) MXPA00004343A (xx)
NO (1) NO317095B1 (xx)
NZ (1) NZ504338A (xx)
PL (1) PL197661B1 (xx)
PT (1) PT1050531E (xx)
SI (1) SI1050531T1 (xx)
ZA (1) ZA200002207B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687513B1 (en) 2004-10-21 2010-03-30 University Of Notre Dame Du Lac Aminopyridinium ionic liquids
US7812098B2 (en) * 2006-03-31 2010-10-12 Depuy Products, Inc. Bearing material of medical implant having reduced wear rate and method for reducing wear rate
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US20090118331A1 (en) * 2007-11-02 2009-05-07 Crooks Peter A Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases, Pathologies, and Drug Abuse
WO2009061906A2 (en) * 2007-11-06 2009-05-14 Mayo Foundation For Medical Education And Research Treating protein misfolding diseases
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
WO2010087315A1 (ja) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 抗アルツハイマー病剤
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
US20120035187A1 (en) * 2009-01-29 2012-02-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-neurodegenerative disease agent
EP3982949A4 (en) * 2019-06-14 2023-10-11 Disarm Therapeutics, Inc. MRSA1 INHIBITORS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840523A (en) * 1973-04-25 1974-10-08 Richardson Merrell Inc Tricyclic arylalkylene lactamimides
US4082806A (en) 1975-12-18 1978-04-04 Wright State University Preparation of tetraketones
JPS5328177A (en) * 1976-08-25 1978-03-16 Teijin Ltd Optical active piperidine derivatives and their preparation
DE58902111D1 (de) * 1988-03-16 1992-10-01 Ciba Geigy Ag Thioverbindungen.
EP0346791B1 (en) * 1988-06-14 1994-04-06 G.D. Searle & Co. 1,2-diarylethylamines for treatment of neurotoxic injury
JP2522690B2 (ja) 1988-06-16 1996-08-07 富士写真フイルム株式会社 ハロゲン化銀カラ―写真感光材料
US5414005A (en) * 1993-10-28 1995-05-09 Dynagen, Inc. Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
FR2756826B1 (fr) * 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
JP2001511159A (ja) * 1997-02-07 2001-08-07 シナプス・ファーマシューティカルズ・インターナショナル・インコーポレイテッド オキシムを含むシナプス機能障害の処置用医薬組成物
JPH10287634A (ja) * 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SI0915088T1 (en) * 1997-10-31 2002-12-31 F. Hoffmann-La Roche Ag D-proline derivatives
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
BR0002287A (pt) 2001-01-02
ZA200002207B (en) 2000-11-14
JP3533361B2 (ja) 2004-05-31
CA2308867A1 (fr) 2000-11-05
US20030139408A1 (en) 2003-07-24
US20020040036A1 (en) 2002-04-04
JP2000355579A (ja) 2000-12-26
CN1277192A (zh) 2000-12-20
NZ504338A (en) 2001-06-29
JP2002179652A (ja) 2002-06-26
US20030181484A1 (en) 2003-09-25
AU764388B2 (en) 2003-08-14
HU0001789D0 (en) 2000-07-28
EA200000389A3 (ru) 2001-02-26
US20050004168A1 (en) 2005-01-06
PT1050531E (pt) 2005-03-31
DE60015844T2 (de) 2005-10-27
DK1050531T3 (da) 2005-03-21
KR20010020808A (ko) 2001-03-15
KR100472519B1 (ko) 2005-03-07
AU3255200A (en) 2000-11-09
HUP0001789A2 (en) 2001-03-28
DE60015844D1 (de) 2004-12-23
US6511992B2 (en) 2003-01-28
ES2233302T3 (es) 2005-06-16
CN100371326C (zh) 2008-02-27
EA200000389A2 (ru) 2000-12-25
EA003053B1 (ru) 2002-12-26
EP1050531B1 (fr) 2004-11-17
NO317095B1 (no) 2004-08-09
NO20002351L (no) 2000-11-06
US6638946B2 (en) 2003-10-28
US20020035123A1 (en) 2002-03-21
MXPA00004343A (es) 2002-03-08
ATE282595T1 (de) 2004-12-15
EP1050531A1 (fr) 2000-11-08
FR2793245B1 (fr) 2002-10-11
PL339994A1 (en) 2000-11-06
CA2308867C (fr) 2006-03-14
FR2793245A1 (fr) 2000-11-10
NO20002351D0 (no) 2000-05-04
US6734196B2 (en) 2004-05-11
US6323220B1 (en) 2001-11-27
PL197661B1 (pl) 2008-04-30
HUP0001789A3 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
DK131893A (da) 2-(Substitueret methyl)-4-(substitueret ethoxy)-5-(lavere alkyl)-pyridinforbindelser, farmaceutisk præparat, som indeholder sådanne samt anvendelse af en sådan forbindelse til fremstilling af et farmaceutisk præparat
MXPA03010584A (es) Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas.
RU98119523A (ru) Соединения пиперазина и пиперидина
ECSP055644A (es) Derivados de la quinolil-propil-piperidina y su utilización
RU98117621A (ru) Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт
CO5670367A2 (es) Derivados de acido fenoxiacetico
CA2404125A1 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
MY101299A (en) Herbicidal pyridine compounds
AU679761B2 (en) 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands
KR870001196A (ko) 피리딘 화합물과 그의 제법 및 그를 함유하는 약학조성물
SI1050531T1 (en) Pyridine and piperidine derivatives for treating neurodegenerative diseases
UA66756C2 (uk) Сполуки піперазину та піперидину, спосіб одержання сполук та спосіб лікування розладів центральної нервової системи
KR920016422A (ko) N-페닐카바메이트 화합물, 이의 제조방법 및 유해한 유기체를 방제하기 위한 살균 조성물
KR930004262A (ko) 메타노안트라센 화합물
KR970704692A (ko) 류코트리엔 생합성의 억제제로서의 이미녹시카복실레이트 및 이의 유도체(Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis)
GB1319026A (en) Imidazole derivatives
CA2409842A1 (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
ATE202564T1 (de) Aminomethylheterozyclischederivate, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
CA1246583A (en) 4-ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND THEIR DERIVATIVES
KR880001593A (ko) 4-(아로일아미노)피페리딘부탄아미드 유도체
KR930004234A (ko) 메타노안트라센 화합물
DK412581A (da) Ethenylimidazolderivater og fremgangsmaade til fremstilling heraf
ATE20063T1 (de) 3-pyridyl-5-alkoxy(oder phenoxy- oder aralkyloxy- )pyrazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
MY128754A (en) Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-aryl-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines
ATE275542T1 (de) Arthropodische carboxanilide